Is there any medicine for gynaecomastia? This is a question many men and adolescents ask when faced with the physical and psychological burden of enlarged breast tissue. Gynaecomastia — the benign growth of glandular breast tissue in males — is more common than often recognised, affecting males across all age groups. While no medicine is specifically licensed in the UK for this condition, certain off-label pharmacological options are used by specialists in appropriate cases. This article outlines the medicines available, how effective they are, when medication may not be suitable, and what other treatment pathways exist on the NHS.

What Is Gynaecomastia and What Causes It?

Gynaecomastia is benign glandular breast tissue enlargement in males caused by an imbalance between oestrogen and androgen activity. Common causes include puberty, ageing, certain medications, and underlying medical conditions such as hypogonadism or liver disease.

Gynaecomastia refers to the benign enlargement of glandular breast tissue in males. It is a relatively common condition that can affect males at any age, from newborns and adolescents to older adults. It is important to distinguish true gynaecomastia — which involves actual glandular tissue growth — from pseudogynaecomastia, which is caused by excess fatty tissue and is typically associated with obesity.

The condition arises from an imbalance between oestrogen and androgen (testosterone) activity in breast tissue. Even though males produce small amounts of oestrogen naturally, any shift in this hormonal ratio can stimulate breast tissue growth. Common causes include:

• Puberty — hormonal fluctuations during adolescence are the most frequent cause in younger males

• Ageing — testosterone levels naturally decline with age, altering the oestrogen-to-androgen ratio

• Medications — including spironolactone, cimetidine, some antipsychotics, anabolic steroids, and certain antiretrovirals

• Medical conditions — such as hypogonadism (including Klinefelter syndrome), hyperthyroidism, liver cirrhosis, chronic kidney disease, or hCG-secreting testicular tumours

• Recreational substances — cannabis has been associated with gynaecomastia in some reports, though the evidence is inconsistent and a direct causal link has not been firmly established; alcohol misuse may also contribute via effects on liver function and hormone metabolism

In many adolescent cases, gynaecomastia resolves spontaneously within one to two years without any treatment. However, when it persists, causes significant psychological distress, or is linked to an underlying condition, further investigation and management become necessary.

A thorough clinical assessment is essential before any treatment is considered. This should include a detailed medication and substance history, clinical examination of the breasts and testes, and relevant blood tests. Core investigations typically include testosterone, LH, FSH, oestradiol, prolactin, thyroid function tests (TFTs), liver function tests (LFTs), renal function (U&Es), and sex hormone-binding globulin (SHBG) where indicated. Serum hCG should be measured when a testicular tumour or other hCG-secreting malignancy is suspected. Testicular ultrasound may also be arranged where clinically appropriate.

Medicines Used to Treat Gynaecomastia in the UK

No medicine is specifically licensed by the MHRA for gynaecomastia; tamoxifen is the most widely used off-label option, prescribed by specialists at 10–20 mg daily for three to six months in early-stage cases.

There is currently no medicine specifically licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of gynaecomastia in the UK. However, several medicines are used off-label by specialists, particularly in cases where the condition is recent in onset (typically within the first one to two years) and where glandular tissue has not yet become fibrotic.

Tamoxifen is the most widely used pharmacological option in clinical practice. It is a selective oestrogen receptor modulator (SERM) that works by competitively blocking oestrogen receptors in breast tissue, thereby reducing the oestrogenic stimulation responsible for glandular proliferation. When used by specialists for this indication, typical regimens involve 10–20 mg once daily (or 10 mg twice daily) for approximately three to six months, though duration is determined on an individual basis. Tamoxifen is subject to clinically significant drug interactions — notably with potent CYP2D6 inhibitors (such as fluoxetine and paroxetine) — and a full medication review should be undertaken before prescribing.

Raloxifene, another SERM, has also been used in some cases, typically at 60 mg once daily (off-label). Some small studies suggest outcomes comparable to tamoxifen, but the evidence base is limited, heterogeneous, and largely derived from non-randomised studies; no clear superiority over tamoxifen has been established.

Aromatase inhibitors such as anastrozole or letrozole reduce the peripheral conversion of androgens to oestrogens. These have been explored primarily in adolescent gynaecomastia linked to specific conditions such as aromatase excess syndrome, but their routine use in adults is not well supported by robust clinical data and they are not considered standard first-line agents. Their use should be restricted to specific endocrine indications under specialist supervision.

Key safety considerations for these medicines include:

• SERMs (tamoxifen and raloxifene): risk of venous thromboembolism (VTE), hot flushes, and leg cramps; tamoxifen should be used with caution in those with a personal or family history of thromboembolic disease, and interactions with CYP2D6 inhibitors must be reviewed

• Aromatase inhibitors: potential adverse effects on bone mineral density, particularly relevant in younger males; bone health should be assessed if prolonged use is considered

These medicines are prescribed on a case-by-case basis, usually following specialist referral. Self-medicating with any of these agents — including those purchased online — carries significant risks and is strongly discouraged. Any pharmacological treatment should be initiated and monitored by a qualified healthcare professional.

If you experience any suspected side effects from a prescribed medicine, you can report these to the MHRA via the Yellow Card Scheme at yellowcard.mhra.gov.uk or through the Yellow Card app.

How Effective Are These Treatments?

Pharmacological treatment is most effective in the active proliferative phase within the first 12 months, with tamoxifen showing partial or complete response in some patients; once fibrosis occurs, medicines are unlikely to produce meaningful improvement.

The effectiveness of medical treatment for gynaecomastia is closely tied to the duration and stage of the condition at the time of intervention. Evidence suggests that pharmacological therapy is most beneficial during the active, proliferative phase — generally within the first 12 months of onset — before fibrous stromal tissue replaces the glandular component. Once fibrosis has occurred, medicines are unlikely to produce meaningful improvement.

Clinical studies indicate that tamoxifen can achieve a reduction in breast tissue volume and associated tenderness in a proportion of patients treated during the early phase. Some published studies report partial or complete response in a majority of patients, though it is important to note that these figures are derived from small, heterogeneous, and often uncontrolled studies; the quality of evidence varies and results may not generalise to all patients. Benefits are most consistently observed in those with early, tender, actively proliferating gynaecomastia.

Raloxifene has shown broadly comparable outcomes to tamoxifen in some studies, but comparative data are limited and inconsistent, and superiority of either agent over the other has not been reliably established.

Aromatase inhibitors have demonstrated benefit primarily in specific paediatric or adolescent populations with identifiable hormonal abnormalities, and their use in the general adult population is not well supported by robust clinical data.

It is also worth noting that:

• Symptom relief (particularly pain and tenderness) may occur even when visible tissue reduction is incomplete

• Psychological benefit from treatment — including improved body image and reduced distress — is a clinically relevant outcome that should not be overlooked

• Recurrence is possible if the underlying hormonal cause is not addressed

Given the off-label nature of these treatments and the variability in individual response, realistic expectations should be discussed with patients prior to commencing any pharmacological therapy. Further information on evidence and management thresholds is available via NICE Clinical Knowledge Summaries (CKS) on gynaecomastia.

When Medication May Not Be Suitable

Medication is unsuitable for long-standing fibrotic gynaecomastia, pseudogynaecomastia caused by fatty tissue, or in patients with contraindications such as a history of venous thromboembolism or significant drug interactions.

Worried about interactions with other medications? Speak to one of our pharmacists →

Medication is not appropriate for all presentations of gynaecomastia, and there are several circumstances in which pharmacological treatment would be considered unsuitable or unlikely to be beneficial.

Firstly, as noted above, long-standing gynaecomastia — typically present for more than 12 to 24 months — is associated with fibrotic changes in the breast tissue. At this stage, the tissue is no longer hormonally responsive, and medicines such as tamoxifen are unlikely to produce a meaningful reduction in breast size. In these cases, surgical intervention is generally the more appropriate option.

Secondly, pseudogynaecomastia caused by adipose (fatty) tissue rather than true glandular proliferation will not respond to hormonal or anti-oestrogenic medications. Weight management and lifestyle modification are the primary approaches in this context.

Thirdly, individuals with certain medical contraindications may not be suitable candidates for SERMs or aromatase inhibitors. For example:

• Tamoxifen and raloxifene carry a risk of thromboembolic events; an individual VTE risk assessment should be undertaken, and these medicines should be used with caution — or avoided — in those with a history of deep vein thrombosis or pulmonary embolism. Common adverse effects of SERMs also include hot flushes and leg cramps.

• Aromatase inhibitors may adversely affect bone mineral density, particularly in younger males; if use is considered by a specialist, baseline bone health assessment and appropriate monitoring (including vitamin D status and, where prolonged use is anticipated, DEXA scanning) should be discussed.

• Drug interactions must be carefully reviewed, especially in patients on multiple medications; in particular, potent CYP2D6 inhibitors can significantly affect tamoxifen metabolism.

Finally, if gynaecomastia is secondary to a prescribed medication, the most appropriate first step is to review and, where clinically safe, discontinue or substitute the causative drug — rather than adding further pharmacological agents. This decision should always be made in consultation with the prescribing clinician and never by the patient independently.

Other Treatment Options Available on the NHS

Surgery — subcutaneous mastectomy, liposuction, or both — is the most definitive treatment for gynaecomastia, though NHS funding depends on local ICB commissioning policies and documented psychological or functional impact.

For patients in whom medication is not suitable or has not produced adequate results, other treatment pathways may be considered. It is important to understand, however, that NHS provision for gynaecomastia treatment — particularly surgical intervention — is subject to local Integrated Care Board (ICB) commissioning policies and is not universally available for cosmetic indications.

Surgery is the most definitive treatment for gynaecomastia, particularly in long-standing or fibrotic cases. The standard surgical approach involves either subcutaneous mastectomy (removal of glandular tissue), liposuction, or a combination of both, depending on the composition of the breast enlargement. NHS funding for surgery is typically considered only when the condition causes significant and documented psychological distress or functional impairment, and when conservative measures have been exhausted. Access varies by local ICB policy, and in some areas an Individual Funding Request (IFR) may be required if standard commissioning criteria are not met. Prerequisites commonly include weight stability, documented duration of symptoms, and a formal assessment of psychological impact. Patients may be referred to a plastic or breast surgeon following assessment.

Conservative measures such as compression garments may help manage discomfort and self-consciousness while awaiting further assessment or treatment decisions, and are worth discussing with a clinician.

Psychological support is an important but often underutilised component of management. Gynaecomastia can have a considerable impact on self-esteem, body image, and mental health, particularly in adolescents and young adults. Referral to a clinical psychologist or counselling service may be appropriate, especially while awaiting further treatment.

Addressing underlying causes remains central to management. Where gynaecomastia is linked to an identifiable condition — such as hypogonadism, hyperprolactinaemia, or liver disease — treating the primary disorder may lead to partial or complete resolution of breast tissue changes.

Patients are encouraged to discuss all available options with their GP or specialist, taking into account the duration of symptoms, the degree of physical and psychological impact, and any relevant comorbidities.

When to See a GP About Gynaecomastia

See your GP promptly if breast enlargement persists, is painful, involves a hard or irregular lump, or is accompanied by nipple discharge; early assessment is important to identify underlying causes and maximise the treatment window.

Many men and adolescents feel embarrassed about gynaecomastia and may delay seeking medical advice. However, early assessment is important — both to identify any underlying cause and to maximise the window during which medical treatment may be effective.

You should make an appointment with your GP if you notice:

• Enlargement or swelling of one or both breasts that persists or progresses over several weeks

• Breast tenderness or pain that is affecting daily life or sleep

• A hard, irregular, or rapidly growing lump in the breast — this requires prompt assessment to exclude malignancy, which, although rare in males, does occur

• Nipple discharge of any kind

• Symptoms alongside other changes such as unexplained weight loss, fatigue, or changes in libido or sexual function

Your GP will typically take a full medical and medication history, perform a clinical examination (including examination of the breasts and testes), and arrange relevant investigations. Core blood tests include testosterone, LH, FSH, oestradiol, prolactin, TFTs, LFTs, renal function (U&Es), and SHBG where indicated. Serum hCG should be considered where a testicular or other hCG-secreting tumour is suspected. Testicular ultrasound may also be arranged where clinically appropriate.

If an underlying cause is identified, appropriate referral — for example, to endocrinology, urology, or oncology — will be arranged. If no secondary cause is found and the condition is causing distress, referral to a specialist with an interest in gynaecomastia management may be considered.

In line with NICE guidance on suspected cancer recognition and referral (NG12), GPs should consider a suspected cancer pathway referral (two-week wait) for men aged 50 and over who present with a unilateral, hard subareolar mass, with or without nipple or skin changes. Any male with a suspicious breast finding should be referred urgently to a breast clinic for triple assessment (clinical examination, imaging, and tissue sampling as appropriate). Do not delay seeking advice if you are concerned — early assessment is always the safest course of action.

Frequently Asked Questions